Publicações

Efficacy and Safety of Ixazomib plus Lenalidomidedexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) by Cytogenetic Risk Status in the Global Phase Iii Tourmaline-Mm1 Study.

AuthID
P-00R-HSN

Author(s)

Richardson, PG

Avet Loiseau, H

Palumbo, A

Viterbo, L

Nagler, A

Ganly, P

Ben Yehuda, D

Miguel, JS

Rajkumar, SV

Langer, C

Berg, D

Lin, JC

Van De Velde, H

Esseltine, DL

di Baccot, A

Moreau, P

Tipo de Documento

Abstract

Year published

2016

Publicado

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 34, Número: 15

Conference

Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: JUN 03-07, 2016, Location: Chicago, IL, Patrocinadores: Amer Soc Clin Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1200/jco.2016.34.15_supp1.8018

Wos: WOS:000404711505174

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Efficacy and Safety of Ixazomib plus Lenalidomidedexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) by Cytogenetic Risk Status in the Global Phase Iii Tourmaline-Mm1 Study.

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Efficacy and Safety of Ixazomib plus Lenalidomidedexamethasone (Ird) Vs Placebo-Rd in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (Rrmm) by Cytogenetic Risk Status in the Global Phase Iii Tourmaline-Mm1 Study.

Links Úteis

Ajuda